Michalis Kontos

Prof. Michalis Kontos


Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 March 2021 in Cancers
Verified
Journal Article
Open access
PDF file
Maggie Banys-PaluchowskiMaggie Banys-Paluchowski
Maggie Banys-Paluchowski
MGMaria Luisa Gasparri
Maria Luisa Gasparri
JBJana de Boniface
Jana de Boniface
Oreste D. GentiliniOreste D. Gentilini
Oreste D. Gentilini
ESElmar Stickeler
Elmar Stickeler
TGthe AXSANA Study Group
the AXSANA Study Group
In the last two decades, surgical methods for axillary staging in breast cancer patients have become less extensive, and full axillary lymph node dissection (ALND) is confined to selected patients. In initially node-positive patients undergoing neoadjuvant chemotherapy, however, the optimal management remains unclear. Current guidelines vary widely, endorsing different strategies. We performed a literature review on axillary staging strategies and their place in international recommendations. This overview defines knowledge gaps associated with specific procedures, summarizes currently ongoing clinical trials that address these unsolved issues, and provides the rationale for further research. While some guidelines have already implemented surgical de-escalation, replacing ALND with, e.g., sentinel lymph node biopsy (SLNB) or targeted axillary dissection (TAD) in cN+ patients converting to clinical node negativity, others recommend ALND. Numerous techniques are in use for tagging lymph node metastasis, but many questions regarding the marking technique, i.e., the optimal time for marker placement and the number of marked nodes, remain unanswered. The optimal number of SLNs to be excised also remains a matter of debate. Data on oncological safety and quality of life following different staging procedures are lacking. These results provide the rationale for the multinational prospective cohort study AXSANA initiated by EUBREAST, which started enrollment in June 2020 and aims at recruiting 3000 patients in 20 countries (NCT04373655; Funded by AGO-B, Claudia von Schilling Foundation for Breast Cancer Research, AWOgyn, EndoMag, Mammotome, and MeritMedical).

24 May 2022 in The Lancet Global Health
Verified
Journal Article
Open access
CSCatherine A Shaw
Catherine A Shaw
RPRiinu Pius
Riinu Pius
TDThomas M Drake
Thomas M Drake
LNLisa Norman
Lisa Norman
AAAdesoji O Ademuyiwa
Adesoji O Ademuyiwa
JLJean Wilguens Lartigue
Jean Wilguens Lartigue
Early death after cancer surgery is higher in low-income and middle-income countries (LMICs) compared with in high-income countries, yet the impact of facility characteristics on early postoperative outcomes is unknown. The aim of this study was to examine the association between hospital infrastructure, resource availability, and processes on early outcomes after cancer surgery worldwide. A multimethods analysis was performed as part of the GlobalSurg 3 study—a multicentre, international, prospective cohort study of patients who had surgery for breast, colorectal, or gastric cancer. The primary outcomes were 30-day mortality and 30-day major complication rates. Potentially beneficial hospital facilities were identified by variable selection to select those associated with 30-day mortality. Adjusted outcomes were determined using generalised estimating equations to account for patient characteristics and country-income group, with population stratification by hospital. Between April 1, 2018, and April 23, 2019, facility-level data were collected for 9685 patients across 238 hospitals in 66 countries (91 hospitals in 20 high-income countries; 57 hospitals in 19 upper-middle-income countries; and 90 hospitals in 27 low-income to lower-middle-income countries). The availability of five hospital facilities was inversely associated with mortality: ultrasound, CT scanner, critical care unit, opioid analgesia, and oncologist. After adjustment for case-mix and country income group, hospitals with three or fewer of these facilities (62 hospitals, 1294 patients) had higher mortality compared with those with four or five (adjusted odds ratio [OR] 3·85 [95% CI 2·58–5·75]; p<0·0001), with excess mortality predominantly explained by a limited capacity to rescue following the development of major complications (63·0% vs 82·7%; OR 0·35 [0·23–0·53]; p<0·0001). Across LMICs, improvements in hospital facilities would prevent one to three deaths for every 100 patients undergoing surgery for cancer. Hospitals with higher levels of infrastructure and resources have better outcomes after cancer surgery, independent of country income. Without urgent strengthening of hospital infrastructure and resources, the reductions in cancer-associated mortality associated with improved access will not be realised. National Institute for Health and Care Research.

1 August 2010 in European Journal of Surgical Oncology
Verified
Journal Article
Closed access
MKMichalis Kontos
Michalis Kontos
RLR.S. Lewis
R.S. Lewis
MLM. Lüchtenborg
M. Lüchtenborg
LHL. Holmberg
L. Holmberg
HHH. Hamed
H. Hamed

1 April 2020 in Journal of Plastic, Reconstructive & Aesthetic Surgery
Verified
Journal Article
Closed access
MKMichalis Kontos
Michalis Kontos
SLS. Lanitis
S. Lanitis
ACA. Constantinidou
A. Constantinidou
PSP. Sakarellos
P. Sakarellos
EVE. Vagios
E. Vagios
MFM. Fragoulis
M. Fragoulis

10 January 2021 in Breast Care
Verified
Journal Article
Closed access
PDF file
GKGeorge Kirkilesis
George Kirkilesis
ACAnastasia Constantinidou
Anastasia Constantinidou
MKMichalis Kontos
Michalis Kontos
Introduction: Targeted axillary dissection (TAD) has been proposed as an alternative method for the staging of patients with node-positive breast cancer who undergo neoadjuvant chemotherapy. However, not much is known yet about the false-negative rate (FNR) of the method and the subsequent risk of underestimation of residual axillary disease. Methods: This study reviews published articles with calculations of false negativity of TAD and potential factors that may influence it. Results: The FNR of TAD is usually reported as being <10%, but this calculation is usually based on small study populations. Lower FNR is a common finding along with lower N status, while not enough data are available yet for greater axillary involvement. When a marked node is revealed to be a sentinel lymph node (SLN) at surgery after neoadjuvant chemotherapy (NAC), this seems to be another factor that contributes to reliable TAD. With regard to the methods used to mark the positive node before chemotherapy and retrieval at surgery, there is no clear advantage of one over the other. The availability of relevant resources, the costs, and local legislation must all be taken into account for the selection of the optimal strategy. Conclusion: Although still in its early days, the FNR of TAD can be low, at least in patients with relatively little axillary involvement and when the marked node is the SLN. All reported methods of lymph node marking seem reliable.

1 March 2021 in Maturitas
Verified
Journal Article
Closed access
Meletios P. NigdelisMeletios P. Nigdelis
Meletios P. Nigdelis
Michalis V KaramouzisMichalis V Karamouzis
Michalis V Karamouzis
MKMichalis Kontos
Michalis Kontos
AAAndreas Alexandrou
Andreas Alexandrou
DGDimitrios G. Goulis
Dimitrios G. Goulis
ILIrene Lambrinoudaki
Irene Lambrinoudaki